Prevalence of Multidrug Resistant Micro-organism Carriage in Patients Undergoing an ERCP in Four Different Countries

CompletedOBSERVATIONAL
Enrollment

1,244

Participants

Timeline

Start Date

January 31, 2022

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Drug Resistance, Multiple, BacterialCholangiopancreatography, Endoscopic Retrograde
Interventions
DIAGNOSTIC_TEST

Multidrug-Resistant Organisms (MDRO) testing through rectal and oral/nasal swabs

Pooled throat/nose sample and a rectal sample is taken prior to the ERCP

DIAGNOSTIC_TEST

MDRO-testing duodenal aspirate

Duodenal aspirate is collected from the duodenum, diluted and undiluted. Then cultured for presence of MDRO's

DIAGNOSTIC_TEST

Microbiome through rectal swab

An rectal swab is collected for microbiome purposes

DIAGNOSTIC_TEST

Microbiome testing duodenal aspirate

Duodenal aspirate is collected from the duodenum, diluted and undiluted for microbiome analysis

Trial Locations (4)

15213

UPMC, Pittsburgh

20089

Humanitas research hospital, Milan

500032

AIG hospitals, Hyderabad

3015GD

Erasmus MC, Rotterdam

Sponsors
All Listed Sponsors
collaborator

Boston Scientific Corporation

INDUSTRY

lead

Marco J. Bruno

OTHER